Lilly Profit Beats Analyst Estimates as Cymbalta Sales Rise

Eli Lilly & Co., maker of the schizophrenia medicine Zyprexa, reported second-quarter profit that fell less than analysts estimated after higher sales for the antidepressant Cymbalta helped trim losses from generic competition to its former top-seller.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.